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The Balance of Risks and
Benefits of Drug-Eluting
Versus Bare-Metal Stents
In a recent article entitled “Stent Thrombosis, Myocardial Infarc-
tion, and Death After Drug-Eluting and Bare-Metal Stent Cor-
onary Interventions,” Jensen et al. (1) added another piece of
evidence to the “late stent thrombosis story” based on registry data
of 12,000 patients. Similar to the findings of BASKET-LATE
(Late Clinical Events Related to Late Stent Thrombosis After
Stopping Clopidogrel) (2) and the Swedish registry (3) as well as
several meta-analyses recently published, they found no excess
mortality overall but an excess in very late (12 months) stent
thrombosis and myocardial infarction (MI). In fact, according
to their Figures 1A and 1D (1 ), the event curves for MI and
stent thromboses seem to diverge already after 6 to 9 months as
in BASKET-LATE and the Swedish registry, which were per-
formed before the publication of the Academic Research Consor-
tium (4) definition of very late as being after 1 year. This stresses
the need to separate findings of thrombotic events in the first (6 or)
12 months from later events and suggests not to lump them
together in overall conclusions as in the report by Jensen et al. (1).
Thus, it seems not quite correct, if the authors write in their
discussion that their findings differed from those of BASKET-
LATE, particularly since that study only reported “late” stent
thrombosis and related clinical events after 6 months.
The most important point in their study is, however, the
balance of risks and benefits of drug-eluting versus bare-metal
stents. Unfortunately, they do not present data on clinical events
related to restenosis/target lesion revascularization that would have
to be weighed against late clinical events related to very late stent
thrombosis as has recently been described by Stone et al. (5): the
first year excess in death/MI due to restenosis after bare-metal
stent implantation was exactly balanced by a second and third year
excess in the same hard events due to stent thrombosis of
drug-eluting-stent-treated patients. Again, a similar balance was
calculated from the BASKET/BASKET-LATE experience (2).
Since the rate of death/MI due to restenosis is much lower than
that due to late stent thrombosis, it would be most helpful to the
reader of the article by Jensen et al. (1) if such a balance could be
specified in “hard” clinical events based on this Danish registry. A
major limitation, however, will be the short period of very late
follow-up of only 3 months. Still, the patient and his treating
physician will have to decide upon such outcome data: long-term
clinical—death or MI—risks and benefits.
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Reply
We appreciate the interest of Dr. Pfisterer and colleagues in our
registry study on stent thrombosis, myocardial infarction, and
death after drug-eluting stent (DES) and bare-metal stent (BMS)
coronary interventions (1).
Dr. Pfisterer and colleagues have the following comments to our
study:
1. Early and late thrombotic events should be separated
It is our opinion that the overall conclusions should include the
entire study period and not only a post-hoc selected period.
Moreover, as we are dealing with registry data, we find it
important to focus on total mortality as the most reliable
parameter. Therefore, we concluded that DES, as compared
with BMS, was a safe intervention in a population with 15
months follow-up (1). We are aware that the event curves for
stent thrombosis and myocardial infarction diverge in favor of
the BMS group and, as Dr. Pfisterer and colleagues, we
acknowledge that late stent thrombosis is a problem, albeit
numerically small, after DES implantation. Interestingly, the
event curves of stent thrombosis and MI seem to cross at a later
time point in the Western Denmark Heart registry than in the
Swedish Coronary Angiography and Angioplasty registry (2),
possibly due to a longer clopidogrel treatment time in Den-
mark.
2. No data on clinical events related to restenosis/target lesion
revascularization
We agree that these data are of great interest. It is, however, a
time-consuming task to get a detailed clinical assessment of
reinterventions in our 12,000 patient cohort. Hopefully, we
will be able to describe the delicate safety balance between
stent thrombosis and target lesion revascularization in a future
publication.
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3. Too short follow-up
Our data were collected over a 3-year period during which the
proportion of DES increased from 0% to 75%. In order to
reduce bias during this transition period, we decided to follow
all patients for 15 months. As mentioned in the manuscript
(1), the follow-up period of 15 months may be inadequate for
a comprehensive assessment of possible risks with use of DES.
Consequently, we intend to follow the Western Denmark
Heart registry cohort as long as data are clinically relevant. The
preliminary 2-year results were recently presented at TCT,
basically confirming the 15-month results (3).
Unfortunately, the implementation of DES treatment was not
based on large randomized studies with hard clinical end points
and long-term follow-up. Therefore, to evaluate potential prob-
lems associated with the use of DES, we have to obtain informa-
tion from various scientifically less reliable sources, such as registry
studies, meta-analyses and nonprimary end point results from
randomized trials. The results from the Western Denmark Heart
Registry is one piece of the puzzle and must be interpreted in
combination with results from other registries and outcome from
studies like the BASKET-LATE (Basel Stent Kosten Effektivita¨ts
Trial–Late Thrombotic Events) (4). Based on such combined
sources of data, we may obtain the best available information to
guide our choice of treatment.
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